Rosuvastatin

also known as Crestor · RSV · rosuvastatin calcium · AZD4522 · Cresnon · CRESTOR (brand name for rosuvastatin) · Crestor (rosuvastatin calcium) · Crestor 10mg(Rosuvastatin) · +9 more

Small molecule targets HMGCR via inhibition

Developed for: hyperlipidemia · hypertensive disorder · coronary artery disorder · atherosclerosis · type 2 diabetes mellitus · hyperlipoproteinemia · diabetes mellitus · HIV infectious disease
+121 more
· acute coronary syndrome · venous thromboembolism · coronary atherosclerosis · cardiovascular disorder · atherosclerotic cardiovascular disease · hyperlipidemia, combined, 2 · stroke disorder · metabolic syndrome X · ST-elevation myocardial infarction · statin toxicity · chronic kidney disease · essential hypertension · familial hypercholesterolemia · heart failure · non-small cell lung carcinoma · hepatitis C virus infection · ischemic disease · ischemic stroke · lip disorder · rheumatoid arthritis · swine influenza · transient ischemic attack · carotid stenosis · colorectal cancer · COVID-19 · intracerebral hemorrhage · intracranial arterial disease · low density lipoprotein cholesterol, mild elevation of · post-thrombotic syndrome · pulmonary embolism · systemic lupus erythematosus · thrombotic disease · acute kidney injury · acute respiratory distress syndrome · ankylosing spondylitis · anterior cerebral artery infarction · anti-neutrophil cytoplasmic antibody-associated vasculitis · aortic disorder · arterial disorder · arteriosclerosis disorder · atrial fibrillation · atypical endometrial hyperplasia · brain injury · breast cancer · cerebral infarction · cerebrovascular disorder · chronic obstructive pulmonary disease · cirrhosis of liver · cisplatin toxicity · clonal hematopoiesis of indeterminate potential · cognitive disorder · combined low LDL and fibrinogen · congestive heart failure · coronary stenosis · depressive disorder · diabetic polyneuropathy · end stage renal failure · endometrial carcinoma · endometrial disorder · Friedreich ataxia · heart disorder · heart valve disorder · hepatocellular carcinoma · homozygous familial hypercholesterolemia · hyperlipoproteinemia type 3 · hyperlipoproteinemia type V · hypertriglyceridemia · hypertriglyceridemia 2 · idiopathic spontaneous coronary artery dissection · ileocolitis · infectious disease with sepsis · inherited lipid metabolism disorder · intracranial arteriosclerosis · major depressive disorder · metabolic dysfunction-associated steatohepatitis · metastatic prostate carcinoma · MRI defined brain infarct · myelodysplastic syndrome · myocardial infarction · myocardial ischemia · NAFLD1 · nonobstructive coronary artery disease · paroxysmal atrial fibrillation · periodontitis, chronic, adult · peripheral arterial disease · platinum-induced ototoxicity · precancerous condition · preeclampsia · primary sclerosing cholangitis · proteinuria · pulmonary tuberculosis · rectal cancer · renal artery obstruction · severe pre-eclampsia · sexual disorder · squamous cell carcinoma · systemic sclerosis · ulcerative colitis · vasculogenic impotence · abdominal obesity-metabolic syndrome · acute lung injury · acute myocardial infarction · aortic valve stenosis · Behcet disease · bone disorder · cerebral atherosclerosis · chemotherapy-induced toxicity · chronic periodontitis · dilated cardiomyopathy · disorder of defective peroxisome oxidative status · esophageal varices with bleeding · glaucoma · hypercholesterolemia, familial, 1 · intermediate coronary syndrome · obstructive sleep apnea syndrome · osteoporosis · peripheral neuropathy · platelet disorder, undefined · portal hypertension · prediabetes syndrome · symptomatic heart failure
Investigated by: AstraZeneca · Yuhan Corporation · Boehringer Ingelheim · Pfizer · GlaxoSmithKline · Hanmi Pharmaceutical Company Limited
+387 more
· Merck Sharp & Dohme LLC · Bristol-Myers Squibb · Eli Lilly and Company · Yonsei University · Jeil Pharmaceutical Co., Ltd. · Alvogen Korea · Boryung Pharmaceutical Co., Ltd · National Heart, Lung, and Blood Institute (NHLBI) · Organon and Co · Bayer · Daewoong Pharmaceutical Co. LTD. · IlDong Pharmaceutical Co Ltd · LG Life Sciences · Parexel · Radboud University Medical Center · University of California, San Francisco · Celgene Corporation · Enanta Pharmaceuticals, Inc · Jiangsu HengRui Medicine Co., Ltd. · Shionogi · The Cleveland Clinic · Alexion Pharmaceuticals, Inc. · Autonomous University of San Luis Potosí · Brigham and Women's Hospital · Canadian Institutes of Health Research (CIHR) · CardioVascular Research Foundation, Korea · Chang Gung Memorial Hospital · Chinese University of Hong Kong · Chong Kun Dang Pharmaceutical · Daewon Pharmaceutical Co., Ltd. · Duke University · Fudan University · HK inno.N Corporation · Hoffmann-La Roche · Idorsia Pharmaceuticals Ltd. · Korea University Anam Hospital · Kyungpook National University Hospital · National Cancer Institute (NCI) · Oslo University Hospital · Ottawa Hospital Research Institute · Samsung Medical Center · Sanofi · Seoul National University Hospital · Severance Hospital · Wake Forest University Health Sciences · Aarhus University Hospital · Abbott · Actelion · Addpharma Inc. · Asan Medical Center · Astellas Pharma Global Development, Inc. · Atea Pharmaceuticals, Inc. · Beijing Anzhen Hospital · Biogen · CHEOL WHAN LEE, M.D., Ph.D · Canadian Critical Care Trials Group · Children's Mercy Hospital Kansas City · Chinese Academy of Medical Sciences, Fuwai Hospital · Columbia University · DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · Daiichi Sankyo · Damanhour University · Dong-A ST Co., Ltd. · Emalex Biosciences Inc. · Genentech, Inc. · Guangdong Raynovent Biotech Co., Ltd · Hanlim Pharm. Co., Ltd. · HeartFlow, Inc. · Hyundai Pharm · Janssen Research & Development, LLC · Jemincare · Johns Hopkins University · Khyber Medical University Peshawar · Loxo Oncology, Inc. · all 393 on the full record

Regulatory milestones approvals, filings & regulatory actions · 8 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	EZALLOR SPRINKLE	—	2023-08-04	fda.gov ↗
Label expansions (6)	US (FDA)	CRESTOR	—	2007-11-08 – 2016-05-27	fda.gov ↗
Approved	US (FDA)	CRESTOR	—	2003-08-12	fda.gov ↗

Trials 549 · started per year

today

US approved 2003

199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 07 trials
Phase 0	NCT06538649	Dec 2024 → Oct 2027 expected	ileocolitis	Stanford University	Recruiting	No outcome recorded
Phase 0	NCT05912387	May 2023 → May 2027 expected	inflammatory bowel disease, primary sclerosing cholangitis	Stanford University	Recruiting	No outcome recorded
Phase 0	NCT03772262	Apr → Nov 2018	—	Washington State University	Completed	No outcome recorded
Phase 0	NCT02705547	May 2016 → Aug 2017	Friedreich ataxia	Children's Hospital of Philadelphia	Completed	No outcome recorded
Phase 0	NCT01955759	Dec 2013 → Dec 2014	—	Heart Center BH Tuzla	Unknown	No outcome recorded
Phase 0	NCT01881971	May 2013 → Nov 2015	—	Alison Morris	Completed	No outcome recorded
Phase 0	NCT00689416	Dec 2007 → Jun 2009	atherosclerosis	AstraZeneca	Completed	No outcome recorded
Phase 1256 trials · 2 met primary · 2 missed
Phase 1	NCT07862621	Nov 2026 → Feb 2027 expected	—	Merck Sharp & Dohme LLC	Not yet recruiting	No outcome recorded
Phase 1	NCT07855250	Oct → Nov 2026 expected	—	Sanofi	Recruiting	No outcome recorded
Phase 1	NCT07785830	Sep → Nov 2026 expected	—	Merck Sharp & Dohme LLC	Not yet recruiting	No outcome recorded
Phase 1	NCT07820891	Sep → Nov 2026 expected	—	BeOne Medicines	Recruiting	No outcome recorded
Phase 1	NCT07550816	May → Dec 2026 expected	obesity disorder	Beijing QL Biopharmaceutical Co.,Ltd	Recruiting	No outcome recorded
Phase 1	NCT07565441	May → Nov 2026 expected	autosomal dominant polycystic kidney disease	Jemincare	Not yet recruiting	No outcome recorded
Phase 1	NCT07692685	May → Jun 2026	—	Neurodawn Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT07534592	Apr → Aug 2026 overdue	—	AstraZeneca	Active not recruiting	No outcome recorded
Phase 1	NCT07515339	Apr → Jun 2026	chronic kidney disease	Bayer	Withdrawn	No outcome recorded
Phase 1	NCT07446400	Mar → Jun 2026 overdue	—	Otsuka Pharmaceutical Development & Commercialization, Inc.	Recruiting	No outcome recorded
Show all 256 trials opens the full record — a long page
Phase 1/24 trials
Phase 1/2	NCT06553157	Sep 2024 → Jul 2025	cancer, platinum-induced ototoxicity	Minia University	Completed	No outcome recorded
Phase 1/2	NCT04833764	Jun 2021 → Jun 2025	post-thrombotic syndrome, venous thromboembolism	Khanh Nguyen	Unknown	No outcome recorded
Phase 1/2	NCT02314286	Dec 2014 → Jul 2016	severe pre-eclampsia	Soroka University Medical Center	Unknown	No outcome recorded
Phase 1/2	NCT00990028	Aug 2009 → Jul 2011	brain injury	Autonomous University of San Luis Potosí	Completed	Mixed
Phase 239 trials · 3 met primary · 4 missed
Phase 2	NCT07460960	Mar 2026 → Dec 2027 expected	atherosclerosis, vasculogenic impotence	Lomonosov Moscow State University Medical Research and Educational Center	Recruiting	No outcome recorded
Phase 2	NCT07307989	Aug 2025 → Jul 2029 expected	hyperlipidemia, ischemic stroke	Chang Gung Memorial Hospital	Recruiting	No outcome recorded
Phase 2	NCT06488105	Aug 2024 → Nov 2027 expected	atherosclerosis, hyperlipidemia, lip disorder	Wake Forest University Health Sciences	Recruiting	No outcome recorded
Phase 2	NCT05483010	Feb 2024 → May 2027 expected	clonal hematopoiesis of indeterminate potential, myelodysplastic syndrome	Washington University School of Medicine	Recruiting	No outcome recorded
Phase 2	NCT05832229	Dec 2023 → Aug 2029 expected	alcoholic liver cirrhosis, hepatitis C induced liver cirrhosis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Recruiting	No outcome recorded
Phase 2	NCT06102863	Apr 2023 → Aug 2025 overdue	endometrial disorder	Peking University People's Hospital	Recruiting	No outcome recorded
Phase 2	NCT05514938	Nov 2022 → May 2025	acute coronary syndrome, coronary artery disorder, lip disorder	University of Texas Southwestern Medical Center	Completed	Missed primary
Phase 2	NCT05895123	Nov 2021 → Mar 2023	ST-elevation myocardial infarction	Damanhour University	Completed	No outcome recorded
Phase 2	NCT04824911	Mar 2021 → Feb 2025	stroke disorder	Chang Gung Memorial Hospital	Completed	Met primary
Phase 2	NCT04817904	Nov 2020 → Aug 2021	cisplatin toxicity	Cairo University	Unknown	No outcome recorded
Phase 2	NCT04303806	Oct 2020 → Oct 2022	preeclampsia	Assiut University	Unknown	No outcome recorded
Phase 2	NCT04491643	Sep 2020 → Aug 2023	endometrial carcinoma	Fudan University	Completed	No outcome recorded
Phase 2	NCT04504851	Aug 2020 → Mar 2021	pulmonary tuberculosis	National University Hospital, Singapore	Unknown	Missed primary
Phase 2	NCT03532139	Jul 2018 → Dec 2023	ovarian cancer	Beth Israel Deaconess Medical Center	Completed	No outcome recorded
Phase 2	NCT02901067	Feb 2017 → May 2021	venous thromboembolism	Denver Health and Hospital Authority	Terminated	No outcome recorded
Phase 2	NCT02679664	Nov 2016 → Jan 2020	venous thromboembolism	Ottawa Hospital Research Institute	Unknown	Missed primary
Phase 2	NCT02841774	Nov 2016 → Jun 2021	HIV infectious disease, coronary artery disorder	Matthew Feinstein	Completed	No outcome recorded
Phase 2	NCT02569645	Nov 2015 → Sep 2021	rectal cancer	AHS Cancer Control Alberta	Completed	No outcome recorded
Phase 2	NCT02516826	Aug 2015 → Aug 2018	coronary artery disorder	Samsung Medical Center	Unknown	No outcome recorded
Phase 2	NCT01837823	Jul 2013 → Apr 2015	coronary atherosclerosis, coronary stenosis	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 2	NCT01863225	May → Jun 2013	coronary artery disorder, hyperlipidemia	Resverlogix Corp	Terminated	No outcome recorded
Phase 2	NCT01874743	Mar 2012 → Sep 2013	HIV infectious disease	Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba	Unknown	No outcome recorded
Phase 2	NCT01524653	Mar 2012 → Jul 2016	neoplasm, venous thromboembolism	University of Vermont	Completed	No outcome recorded
Phase 2	NCT01105975	Apr 2010 → Jun 2011	hyperlipidemia	Eli Lilly and Company	Completed	Met primary
Phase 2	NCT00929734	Mar 2010 → Jan 2014	chronic obstructive pulmonary disease	University Hospital, Akershus	Completed	Missed primary
Phase 2	NCT01622777	Feb 2010 → Jan 2011	diabetic polyneuropathy	Alejandra Guillermina Miranda Diaz	Completed	No outcome recorded
Phase 2	NCT01033955	Jan → May 2010	swine influenza	Canadian Critical Care Trials Group	Terminated	No outcome recorded
Phase 2	NCT01798602	Dec 2009 → May 2010	swine influenza	Canadian Critical Care Trials Group	Terminated	No outcome recorded
Phase 2	NCT00951132	Sep 2009 → Dec 2012	depressive disorder	University Hospital, Akershus	Withdrawn	No outcome recorded
Phase 2	NCT00555230	Jul 2007 → Dec 2009	rheumatoid arthritis	Chinese University of Hong Kong	Completed	No outcome recorded
Phase 2	NCT00446940	Dec 2006 → Mar 2007	hepatitis C virus infection	Bader, Ted, M.D.	Completed	No outcome recorded
Phase 2	NCT00357123	Aug 2006 → Jul 2011	infectious disease with sepsis	Autonomous University of San Luis Potosí	Unknown	No outcome recorded
Phase 2	NCT00364559	Aug → Dec 2006	intracerebral hemorrhage	Autonomous University of San Luis Potosí	Completed	No outcome recorded
Phase 2	NCT00315510	Apr 2006 → Aug 2007	ischemic disease	Radboud University Medical Center	Completed	No outcome recorded
Phase 2	NCT00296400	Feb 2006 → Jun 2009	hyperlipidemia	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00296374	Feb 2006 → Mar 2009	diabetes mellitus	AstraZeneca	Completed	No outcome recorded
Phase 2	NCT00184951	Apr 2004 → Jul 2005	HIV infectious disease, hyperlipidemia	Radboud University Medical Center	Completed	No outcome recorded
Phase 2	NCT00176332	Mar 2004 → Dec 2006	heart failure	University of Leipzig	Completed	No outcome recorded
Phase 2	NCT00160745	? → Sep 2006	hyperlipidemia	University of Erlangen-Nürnberg Medical School	Completed	Met primary

Phase 2/36 trials
Phase 2/3	NCT07313124	Dec 2024 → Nov 2025	cardiovascular disorder	Beni-Suef University	Completed	No outcome recorded
Phase 2/3	NCT06834932	Dec 2024 → Feb 2027 expected	hyperlipidemia	AstraZeneca	Active not recruiting	No outcome recorded
Phase 2/3	NCT04883840	Oct 2020 → Oct 2025	ulcerative colitis	Universitaire Ziekenhuizen KU Leuven	Terminated	No outcome recorded
Phase 2/3	NCT04491682	Sep 2020 → Jun 2022	atypical endometrial hyperplasia	Fudan University	Completed	No outcome recorded
Phase 2/3	NCT03521700	Jun 2013 → Dec 2014	renal artery obstruction	Chinese Academy of Medical Sciences, Fuwai Hospital	Completed	No outcome recorded
Phase 2/3	NCT00986999	Sep 2009 → Jan 2015	HIV infectious disease, cardiovascular disorder	University of Hawaii	Terminated	No outcome recorded Stop: Enrollment
Phase 395 trials · 17 met primary · 6 missed
Phase 3	NCT07474649	Sep 2026 → Jun 2028 expected	coronary atherosclerosis, hyperlipidemia, combined, 2	Daiichi Sankyo	Not yet recruiting	No outcome recorded
Phase 3	NCT07232069	Jul 2026 → Jul 2031 expected	atherosclerosis, coronary artery disorder	Duke University	Recruiting	No outcome recorded
Phase 3	NCT07012629	Nov 2025 → Sep 2031 expected	MRI defined brain infarct	Aarhus University Hospital	Recruiting	No outcome recorded
Phase 3	NCT07216482	Nov 2025 → Aug 2026 overdue	hyperlipidemia	Merck Sharp & Dohme LLC	Active not recruiting	No outcome recorded
Phase 3	NCT06646354	Apr → May 2025 overdue	essential hypertension, hyperlipoproteinemia	Hyundai Pharm	Enrolling by invitation	No outcome recorded
Phase 3	NCT06772168	Apr 2024 → Nov 2026 expected	hyperlipidemia, type 2 diabetes mellitus	CMG Pharmaceutical Co. Ltd	Recruiting	No outcome recorded
Phase 3	NCT06698666	Oct 2022 → Dec 2024 overdue	major depressive disorder	Ain Shams University	Recruiting	No outcome recorded
Phase 3	NCT07564726	Aug 2022 → Feb 2024	essential hypertension, hyperlipoproteinemia	Celltrion Pharm, Inc.	Completed	No outcome recorded
Phase 3	NCT05155137	Dec 2021 → Dec 2029 expected	cognitive disorder, stroke disorder	Hospital Moinhos de Vento	Recruiting	No outcome recorded
Phase 3	NCT04964544	Jul 2021 → Mar 2023	low density lipoprotein cholesterol, mild elevation of	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT04319627	Feb 2021 → Jan 2028 expected	post-thrombotic syndrome, thrombotic disease, venous thromboembolism	Ottawa Hospital Research Institute	Recruiting	No outcome recorded
Phase 3	NCT04669041	Dec 2020 → Jun 2022	hyperlipidemia	Sanofi	Completed	Met primary
Phase 3	NCT04472611	Oct 2020 → Mar 2022	COVID-19	Yale University	Completed	Missed primary
Phase 3	NCT04659070	Jul 2020 → May 2022	essential hypertension, hyperlipoproteinemia	Hanlim Pharm. Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT04737408	May 2020 → Aug 2023	coronary artery disorder	Bjarne Linde Noergaard	Unknown	No outcome recorded
Phase 3	NCT04161001	Nov 2019 → Nov 2021	—	Daewoong Pharmaceutical Co. LTD.	Unknown	No outcome recorded
Phase 3	NCT02662894	Oct 2019 → Sep 2020	hyperlipidemia, hypertensive disorder	EMS	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT03872232	Feb 2019 → Aug 2020	essential hypertension, hyperlipoproteinemia	Addpharma Inc.	Completed	No outcome recorded
Phase 3	NCT03037372	Jun 2017 → Jun 2022	HIV infectious disease	Makerere University	Unknown	No outcome recorded
Phase 3	NCT02850081	Jun 2017 → Mar 2020	carotid stenosis, stroke disorder	Columbia University	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT03103256	May 2017 → Apr 2018	hyperlipidemia	Yuhan Corporation	Completed	No outcome recorded
Phase 3	NCT03067688	Apr 2017 → Mar 2018	hyperlipidemia, hypertensive disorder	Yuhan Corporation	Completed	Met primary
Phase 3	NCT03009487	Jan 2017 → Apr 2018	hyperlipidemia, hypertensive disorder	Daewoong Pharmaceutical Co. LTD.	Completed	No outcome recorded
Phase 3	NCT03210532	Oct 2016 → Sep 2017	hyperlipidemia, hypertensive disorder	Daewon Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT03088254	Sep 2016 → Jul 2017	—	Jeil Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02741245	Jun 2016 → Jan 2017	hyperlipidemia	Organon and Co	Completed	Met primary
Phase 3	NCT02748057	May 2016 → Dec 2017	familial hypercholesterolemia	Organon and Co	Completed	No outcome recorded
Phase 3	NCT02749994	Apr 2016 → Feb 2017	hyperlipidemia	IlDong Pharmaceutical Co Ltd	Completed	Met primary
Phase 3	NCT02827903	Jan 2016 → Nov 2017	hyperlipidemia, type 2 diabetes mellitus	Jeil Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02770261	Dec 2015 → Aug 2016	hyperlipidemia, hypertensive disorder	Alvogen Korea	Completed	No outcome recorded
Phase 3	NCT03566316	Nov 2015 → Jun 2017	hyperlipidemia, combined, 2	IlDong Pharmaceutical Co Ltd	Completed	Met primary
Phase 3	NCT02546323	Sep 2015 → Jan 2019	atherosclerosis	AstraZeneca	Completed	Met primary
Phase 3	NCT02434497	Jun 2015 → Nov 2016	homozygous familial hypercholesterolemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT02546648	Feb → Oct 2015	atherosclerosis	McMaster University	Completed	No outcome recorded
Phase 3	NCT02117453	Oct 2014 → Nov 2019	anti-neutrophil cytoplasmic antibody-associated vasculitis	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT03288038	Oct 2014 → Nov 2015	hyperlipidemia	Shin Poong Pharmaceutical Co. Ltd.	Completed	No outcome recorded
Phase 3	NCT02551172	Oct 2014 → Jan 2016	hyperlipidemia	Hanmi Pharmaceutical Company Limited	Unknown	No outcome recorded
Phase 3	NCT03571087	Sep 2014 → Aug 2015	hyperlipoproteinemia	Hanlim Pharm. Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02899455	Jul 2014 → Jun 2016	hyperlipidemia, hypertensive disorder	Hanmi Pharmaceutical Company Limited	Completed	Met primary
Phase 3	NCT02251847	Jul 2014 → Jul 2015	hyperlipidemia	IlDong Pharmaceutical Co Ltd	Unknown	No outcome recorded
Phase 3	NCT02205606	Jun 2014 → Feb 2015	hyperlipidemia	Hanmi Pharmaceutical Company Limited	Completed	No outcome recorded
Phase 3	NCT02126358	May 2014 → Mar 2016	hyperlipidemia, type 2 diabetes mellitus	LG Life Sciences	Completed	No outcome recorded
Phase 3	NCT01914432	Nov 2013 → Jun 2014	hyperlipidemia, hypertensive disorder	Yuhan Corporation	Completed	Met primary
Phase 3	NCT02087540	May 2013 → Dec 2014	hyperlipidemia, hypertensive disorder	IlDong Pharmaceutical Co Ltd	Unknown	No outcome recorded
Phase 3	NCT01420549	Mar 2013 → Nov 2014	hyperlipidemia	Ache Laboratorios Farmaceuticos S.A.	Completed	Met primary
Phase 3	NCT01730053	Nov 2012 → Apr 2014	hyperlipidemia	Regeneron Pharmaceuticals	Completed	Missed primary
Phase 3	NCT01918332	Apr 2012 → Mar 2013	hyperlipidemia, hypertensive disorder	LG Life Sciences	Completed	No outcome recorded
Phase 3	NCT01425398	Nov 2011 → Dec 2013	heart valve disorder	McGill University Health Centre/Research Institute of the McGill University Health Centre	Completed	No outcome recorded
Phase 3	NCT01164540	Feb 2011 → Mar 2013	pulmonary embolism, venous thromboembolism	AstraZeneca	Withdrawn	No outcome recorded
Phase 3	NCT01364220	Aug 2010 → Apr 2013	stroke disorder	Severance Hospital	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT02205775	May 2010 → Mar 2012	coronary artery disorder	G. d'Annunzio University	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT01011478	Mar 2010 → Dec 2014	colorectal cancer, precancerous condition	NSABP Foundation Inc	Terminated	No outcome recorded
Phase 3	NCT01007279	Mar → Sep 2010	myocardial infarction	University of Roma La Sapienza	Completed	No outcome recorded
Phase 3	NCT01078675	Feb 2010 → Feb 2013	familial hypercholesterolemia	AstraZeneca	Completed	Met primary
Phase 3	NCT00783263	Nov 2008 → May 2010	hyperlipidemia	Organon and Co	Completed	Met primary
Phase 3	NCT00812955	Nov 2008 → Jun 2009	hyperlipidemia	AstraZeneca	Completed	Met primary
Phase 3	NCT00984932	Sep 2008 → Jul 2009	systemic sclerosis	University of Alexandria	Completed	No outcome recorded
Phase 3	NCT00683618	May 2008 → Jul 2009	hyperlipidemia	AstraZeneca	Completed	Met primary
Phase 3	NCT00620542	Jan 2008 → Jun 2011	coronary atherosclerosis	AstraZeneca	Completed	Missed primary
Phase 3	NCT00525824	Aug 2007 → Sep 2008	atherosclerosis, coronary artery disorder, hyperlipidemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00491530	Jun 2007 → Nov 2008	hyperlipidemia, combined, 2	Abbott	Completed	No outcome recorded
Phase 3	NCT00355615	Jul 2006 → Jul 2008	familial hypercholesterolemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00296387	Jan 2006 → Oct 2007	acute coronary syndrome	AstraZeneca	Completed	Missed primary
Phase 3	NCT00214604	Feb 2005 → Feb 2007	hyperlipoproteinemia type 3	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00132717	Jan 2005 → Jun 2007	hyperlipidemia	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00115830	Dec 2004 → Feb 2007	atherosclerosis	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 3	NCT00090298	Apr → Dec 2004	hyperlipidemia	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00240305	Apr 2004 → May 2006	hyperlipidemia, metabolic syndrome X	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00228514	Feb 2004 → Jul 2007	heart failure, statin toxicity	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00214630	Dec 2003 → Aug 2007	acute coronary syndrome	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00329173	Nov 2003 → Aug 2004	hyperlipidemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00206310	Sep 2003 → Jul 2007	heart failure	AstraZeneca	Completed	Missed primary
Phase 3	NCT00240266	Aug 2003 → Nov 2004	hyperlipidemia, metabolic syndrome X	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00239330	Jun 2003 → Feb 2005	hyperlipoproteinemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00241488	Jun 2003 → Dec 2005	—	AstraZeneca	Completed	Met primary
Phase 3	NCT00653965	May 2003 → Feb 2005	hyperlipidemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00653588	Apr 2003 → Sep 2004	coronary artery disorder, hyperlipidemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00239681	Feb 2003 → Sep 2008	combined low LDL and fibrinogen	AstraZeneca	Terminated	Met primary
Phase 3	NCT00240292	Feb 2003 → ?	congestive heart failure	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00240331	Jan 2003 → Oct 2008	end stage renal failure	AstraZeneca	Completed	Missed primary
Phase 3	NCT00240279	Jan 2003 → Oct 2008	hyperlipoproteinemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00240318	Nov 2002 → Nov 2005	coronary atherosclerosis	AstraZeneca	Completed	Met primary
Phase 3	NCT00654225	Oct 2002 → Mar 2005	hyperlipidemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00654446	Sep 2002 → Apr 2004	hyperlipidemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00336336	Aug 2002 → Apr 2008	heart failure	Gruppo di Ricerca GISSI	Completed	Mixed
Phase 3	NCT00225589	Aug 2002 → May 2006	hyperlipidemia	AstraZeneca	Completed	Met primary
Phase 3	NCT00654173	Jun 2002 → Sep 2004	hyperlipidemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00654485	May 2002 → Feb 2005	metabolic syndrome X	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00653744	Mar 2002 → Mar 2004	hyperlipidemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00654602	Feb 2002 → Nov 2004	hyperlipidemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00657527	Dec 2001 → Dec 2002	coronary artery disorder, myocardial ischemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00654407	Nov 2001 → Sep 2004	hyperlipoproteinemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00654537	Apr 2001 → Oct 2004	familial hypercholesterolemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00654394	Jan 2000 → Aug 2004	carotid stenosis, hyperlipidemia	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00654303	Aug 1999 → Feb 2005	hyperlipidemia	AstraZeneca	Completed	No outcome recorded

Phase 4113 trials · 7 met primary · 6 missed
Phase 4	NCT07303816	Jun 2026 → Mar 2031 expected	cancer, venous thromboembolism	Brigham and Women's Hospital	Recruiting	No outcome recorded
Phase 4	NCT06767774	Apr 2025 → Aug 2029 expected	atherosclerotic cardiovascular disease, diabetes mellitus	Korea University Anam Hospital	Recruiting	No outcome recorded
Phase 4	NCT06820086	Mar 2025 → Mar 2031 expected	—	Mikk JÜRISSON	Active not recruiting	No outcome recorded
Phase 4	NCT06856772	Feb 2025 → Mar 2028 expected	atherosclerotic cardiovascular disease	Tor Biering-Sørensen	Not yet recruiting	No outcome recorded
Phase 4	NCT06785727	Feb 2025 → Dec 2028 expected	transient ischemic attack	Prof. dr. Nathalie van der Velde	Not yet recruiting	No outcome recorded
Phase 4	NCT06804980	Feb 2025 → Dec 2026 expected	statin toxicity	Minneapolis Heart Institute Foundation	Recruiting	No outcome recorded
Phase 4	NCT06765265	Jan 2025 → Jan 2026 overdue	acute coronary syndrome	King Edward Medical University	Recruiting	No outcome recorded
Phase 4	NCT05613426	Apr 2023 → Jul 2025	ST-elevation myocardial infarction	Henan Institute of Cardiovascular Epidemiology	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT05742841	Mar → Jun 2023	hyperlipidemia	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 4	NCT06273215	Mar 2023 → Dec 2025	diabetes mellitus	Peking University Third Hospital	Unknown	No outcome recorded
Show all 113 trials opens the full record — a long page
Phase not applicable27 trials · 1 met primary · 1 missed
—	NCT07704918	Dec 2026 → Dec 2027 expected	melanoma	University of Colorado, Denver	Not yet recruiting	No outcome recorded
—	NCT07679828	Jul 2026 → Dec 2029 expected	hyperlipidemia, hypertensive disorder, type 2 diabetes mellitus	China Medical University, China	Recruiting	No outcome recorded
—	NCT07401017	Mar → Aug 2026 overdue	hyperlipidemia, statin toxicity	Taipei Medical University WanFang Hospital	Not yet recruiting	No outcome recorded
—	NCT07432516	Feb 2026 → Jun 2033 expected	coronary artery disorder	Yonsei University	Not yet recruiting	No outcome recorded
—	NCT06603363	May 2025 → Oct 2026 expected	coronary atherosclerosis, hyperlipidemia	Prof. Maurovich-Horvat Pál	Recruiting	No outcome recorded
—	NCT06231966	Apr 2024 → May 2026 overdue	peripheral arterial disease	Yonsei University	Recruiting	No outcome recorded
—	NCT05741372	Sep 2023 → Dec 2024	cirrhosis of liver	Boehringer Ingelheim	Completed	No outcome recorded
—	NCT04176978	Apr 2021 → Dec 2022	atherosclerosis, psoriatic arthritis	Chinese University of Hong Kong	Withdrawn	No outcome recorded Stop: Business
—	NCT04699279	Jan 2021 → Dec 2024 overdue	aortic disorder	Nanjing Medical University	Recruiting	No outcome recorded
—	NCT05368545	May 2020 → Apr 2024	coronary artery disorder	Aarhus University Hospital	Completed	No outcome recorded
—	NCT04923152	Jan 2020 → Jan 2021	—	Shiraz University of Medical Sciences	Completed	No outcome recorded
—	NCT03907423	Apr 2019 → Jan 2021	type 2 diabetes mellitus	Rehab Werida	Completed	No outcome recorded
—	NCT06094244	Mar 2017 → Dec 2020	intracerebral hemorrhage	Pomeranian Medical University Szczecin	Completed	No outcome recorded
—	NCT02785874	Sep → Oct 2016	hepatocellular carcinoma	Taipei Medical University WanFang Hospital	Terminated	No outcome recorded Stop: Business
—	NCT02420899	Apr 2015 → Jul 2016	acute coronary syndrome	Beijing Friendship Hospital	Unknown	No outcome recorded
—	NCT02341794	Jan 2015 → Dec 2017	intracranial arterial disease	Tokyo Medical University	Unknown	No outcome recorded
—	NCT01982461	Nov 2013 → Jan 2014	hyperlipoproteinemia	Pin Siang Medical Biotechnology Co., Ltd.	Unknown	No outcome recorded
—	NCT01389388	Jan → Aug 2013	ankylosing spondylitis, arterial disorder	Diakonhjemmet Hospital	Completed	Met primary
—	NCT02305862	Jan 2013 → Dec 2016	arteriosclerosis disorder, diabetes mellitus, lip disorder	Capital Medical University	Unknown	No outcome recorded
—	NCT01613794	Dec 2012 → Dec 2016	pulmonary embolism, venous thromboembolism	Leiden University Medical Center	Completed	No outcome recorded
—	NCT01634906	Jul 2012 → Mar 2013	atherosclerosis, hyperlipidemia	Sint Franciscus Gasthuis	Completed	No outcome recorded
—	NCT01544309	Mar 2012 → Jun 2014	hyperlipidemia	Listen Trial Group	Completed	No outcome recorded
—	NCT01259791	Sep 2010 → Aug 2013	statin toxicity	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Completed	Missed primary
—	NCT00970606	Oct 2009 → Jul 2011	acute respiratory distress syndrome, swine influenza	Gordon Bernard	Terminated	No outcome recorded Stop: Enrollment
—	NCT00554138	Nov 2007 → Mar 2008	—	Radboud University Medical Center	Completed	No outcome recorded
—	NCT00464503	Sep → Oct 2007	statin toxicity	University of Antwerp	Completed	No outcome recorded
—	NCT00371579	Oct 2006 → Oct 2007	hepatitis C virus infection	UMC Utrecht	Withdrawn	No outcome recorded Stop: Enrollment

Phase not stated2 trials
—	NCT00965315	—	cardiovascular disorder	National Taiwan University Hospital	Available	No outcome recorded
—	NCT00934258	—	hyperlipidemia	National Taiwan University Hospital	Available	No outcome recorded
Comparator or background therapy243 trials
Phase 0	NCT06105060 Comparator	Dec 2023 → Jun 2024	metabolic dysfunction-associated steatohepatitis	Beni-Suef University	Completed	No outcome recorded
Phase 0	NCT00783042 Comparator	Oct 2008 → May 2009	atherosclerosis, coronary artery disorder	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT07629999 Background	Jun 2026 → Jun 2027 expected	—	Bristol-Myers Squibb	Not yet recruiting	No outcome recorded
Phase 1	NCT07001787 Comparator	Jun 2025 → Feb 2026 overdue	hyperlipidemia	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Not yet recruiting	No outcome recorded
Phase 1	NCT06899061 Comparator	Mar 2025 → Feb 2026 overdue	high grade malignant neoplasm	AstraZeneca	Active not recruiting	No outcome recorded
Show all 243 trials opens the full record — a long page

Press releases naming this drug 17 releases

Date	Issuer	Release
2021-02-10	AstraZeneca	Divestment of Crestor in Europe to Grünenthal completed astrazeneca.com ↗
2020-12-01	AstraZeneca	Crestor to be divested to Grünenthal in Europe astrazeneca.com ↗
2019-07-15	Sun Pharmaceutical Industries, Inc.	Sun Pharma Launches Ezallor Sprinkle (Rosuvastatin) in the U.S. for People Who Have Difficulty Swallowing sunpharma.com ↗
2017-08-03	Lupin Limited	Lupin receives FDA approval for generic Crestor® tablets lupin.com ↗
2016-07-20	Sun Pharmaceutical Industries, Inc.	Sun Pharma announces US FDA approval for generic Crestor® sunpharma.com ↗
2014-02-10	Daewoong Pharmaceutical Co. LTD.	Daewoong Pharmaceutical received domestic approval for its OLOSTAR, the new complex combining the Olmesatan and rosuvastatin for the first time worldwide daewoong.co.kr ↗
2013-12-26	AstraZeneca	AstraZeneca and Shionogi settle arbitration and extend licence agreement for CRESTOR® astrazeneca.com ↗
2013-03-25	AstraZeneca	AstraZeneca settles litigation over CRESTOR patent astrazeneca.com ↗
2013-03-05	AstraZeneca	Australia Federal Court holds CRESTOR patents invalid astrazeneca.com ↗
2012-12-14	AstraZeneca	CRESTOR US patent upheld by Court of Appeals for the Federal Circuit astrazeneca.com ↗
2010-09-29	Sun Pharmaceutical Industries, Inc.	Sun Pharma announces USFDA tentative approval for generic Crestor® sunpharma.com ↗
2010-06-30	AstraZeneca	CRESTOR Patent Upheld By US Court astrazeneca.com ↗
2010-04-27	AstraZeneca	Crestor™ Gains New EU Indication to Prevent Major Cardiovascular Events in High Risk Patients astrazeneca.com ↗
2010-02-09	AstraZeneca	US FDA Approves New Indication for Crestor (Rosuvastatin Calcium) astrazeneca.com ↗
2009-12-15	AstraZeneca	Favourable Vote From FDA Advisory Committee On Benefit/Risk Of CRESTOR In JUPITER Study astrazeneca.com ↗
2009-12-11	AstraZeneca	Advisory Committee Briefing Materials For Crestor sNDA Available On US FDA Web Site astrazeneca.com ↗
2009-10-16	AstraZeneca	US Food and Drug Administration Approves CRESTOR for Use in Pediatric Patients with Heterozygous Familial Hypercholesterolemia astrazeneca.com ↗

Evidence & citations 22 cited values

Every value below carries the sentence it was read from. 800 sources stand behind the page.

Field	Value	Cited text
Known as	Rosuvastatin	“Ten healthy Caucasian subjects were orally dosed with the CIME combination (caffeine-CYP1A2, repaglinide-CYP2C8, tolbutamide-CYP2C9, omeprazole-CYP2C19,...” PMID 25465228 ↗ Dec 2014 783 “The purpose of this study is to determine whether administration of lapaquistat acetate co-administered with atorvastatin, rosuvastatin or simvastatin (stable statin therapy)...” NCT00249899 ↗ “Pharmacokinetics of a Fixed-Dose Combination Product of Amlodipine, Losartan, Ezetimibe, and Rosuvastatin and Its Comparison with Co-administration of Four Individual...” PMID 38775910 ↗ May 2024 “Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20...” NCT00850460 ↗ “The study will evaluate the pharmacokinetics (PK) and safety effects of co-administration of radiprodil with oral midazolam, rosuvastatin, warfarin, digoxin, and omeprazole in...” NCT06975605 ↗ “Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin...” NCT02072161 ↗ “The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and...” PMID 29150250 ↗ Nov 2017 “A Randomized, Open Label, Single Dose, 2X2 Cross-over Study to Compare Pharmacokinetics Between Rosuvastatin 10mg and Omega-3 1g Co-administration and HCP1007 in Healthy Male Volunteers” NCT01548157 ↗ “Treatment effect of olmesartan to hypertension and rosuvastatin to dyslipidemia is already proven in previous studies, and these medication does not have interaction with each other.” NCT04061824 ↗ “First line agents will be generic statin medications (atorvastatin or rosuvastatin)whichever is covered by the participant's health insurance), barring contraindication to their use.” NCT06975111 ↗ “The initial recommended therapy is 20mg atorvastatin/10mg rosuvastatin plus Ezetimibe or PCSK9i, and the type and dosage of drugs can be adjusted according to the situation.” NCT06896708 ↗ Show 773 more sources
Known as	AZD4522	“Rosuvastatin (AZD4522)” NCT01164540 ↗
Known as	Cresnon	“Rosuvastatin(Cresnon®)” NCT02280590 ↗
Known as	Crestor	“The purpose of the study is to investigate the effects of atorvastatin (Lipitor) and rosuvastatin (Crestor), United States Food and Drug Administration (FDA) approved drugs...” NCT00115830 ↗ 42 “Both drugs have been in use for decades for gout and pericarditis (colchicine) and hyperlipidemia, coronary disease (CAD) and diabetes (rosuvastatin/Crestor), and have been...” NCT04472611 ↗ “Pharmacodynamics and Pharmacokinetics of Combined Use of Rosuvastatin (Crestor) and Lopinavir/Ritonavir (Kaletra) in HIV-infected Patients With Hyperlipidemia (ROSALKA)” NCT00184951 ↗ “Name of Drugs: Niaspan (niacin extended-release tablets), Lipitor® (atorvastatin), Zocor® (simvastatin), Zetia™ (ezetimibe), and Crestor® (rosuvastatin)” NCT00079638 ↗ “The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year” NCT00296374 ↗ “co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Crestor Tab. 20mg(Rosuvastatin 20mg) and placebo of Olmesartan 40mg” NCT03009487 ↗ “A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome” NCT00240305 ↗ “Rosuvastatin (Crestor) was chosen as the study drug over others for pharmacokinetic and side effect profile.” NCT00978419 ↗ “single-dose rosuvastatin (Crestor®), a sensitive Breast Cancer Resistance Protein (BCRP) Substrate” NCT02300363 ↗ “Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin) followed by DWJ1351” NCT02665832 ↗ “Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)” NCT03707899 ↗ Show 32 more sources
Known as	CRESTOR (brand name for rosuvastatin)	“CRESTOR (brand name for rosuvastatin)” NCT00658463 ↗
Known as	Crestor (rosuvastatin calcium)	“Crestor® (rosuvastatin calcium)” NCT01899027 ↗
Known as	Crestor 10mg(Rosuvastatin)	“Crestor 10mg(Rosuvastatin)” NCT01992211 ↗
Known as	Crestor Tablet 20 mg manufactured by Astrazeneca	“Crestor Tablet 20 mg manufactured by Astrazeneca” NCT01466608 ↗
Known as	Monorova Tab	“Monorova® Tab (rosuvastatin 10mg) qd for 8 weeks” NCT03446261 ↗
Known as	R= Rosuvastatin = brand name : Crestor	“R= Rosuvastatin = brand name : Crestor” NCT01918709 ↗
Known as	Rosu	“triple-combination of olmesartan/amlodipine/rosuvastatin (Olme/Amlo/Rosu)” PMID 37814541 ↗ Jan 2023
Known as	rosuvastatin (Crestor)	“rosuvastatin (Crestor)” NCT00127218 ↗
Known as	rosuvastatin calcium	“The combination product will be a Drug (Rosuvastatin calcium 5 mg) and Software as a Medical Device (Web App that features a Technology-Assisted Self-Selection (TASS) tool).” NCT04964544 ↗ 9 “a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)” NCT03216304 ↗ “Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)” NCT06225635 ↗ “Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab” NCT01925300 ↗ “Rosuvastatin Calcium 20mg, QD” NCT03026933 ↗ “Drug: Rosuvastatin Calcium” NCT05828303 ↗ “Drug: rosuvastatin calcium” NCT01078675 ↗ NCT07565441 ↗ NCT00719693 ↗ NCT04603508 ↗
Known as	Rosuvastatin calcium Tablets	“Rosuvastatin calcium Tablets, 10 mg, once a night, orally.” NCT07309042 ↗
Known as	ROVASRO	“ROVASRO, generic formulation of rosuvastatin” NCT03949374 ↗
Known as	RSV	“The aim of this study was to evaluate the blood pressure-lowering and cholesterol-lowering effects of a fixed-dose combination therapy using candesartan (CND)/rosuvastatin...” PMID 31307833 ↗ Jul 2019 10 “The present study aims to explore the efficacy of 1.2% rosuvastatin (RSV) gel local drug delivery as an adjunct to SRP in smokers with chronic periodontitis (CP).” NCT03043196 ↗ “Therefore, we sought to identify predictors of significant hsCRP reduction after the use of rosuvastatin (RSV)/amlodipine (AML) and atorvastatin (ATV)/AML.” PMID 40429358 ↗ May 2025 “The present study evaluated the efficacy of N-acetyl cysteine (NAC) and rosuvastatin (RSV) compared with conventional vitamin E in patients with NASH.” PMID 40480879 ↗ Jun 2025 “Rosuvastatin (RSV) is one of new synthetic, second-generation, sulfur-containing, hydrophilic statin” NCT02283515 ↗ “fimasartan 60 mg/amlodipine 10 mg + rosuvastatin 20 mg (FMS/ALD + RSV) as study group” PMID 36451242 ↗ Dec 2022 “After SRP, 1.2% Rosuvastatin (RSV) gel was delivered subgingivally into the pocket” NCT02600520 ↗ “The aim of this study was to evaluate the efficacy of rosuvastatin (RSV)” PMID 23323877 ↗ Feb 2013 “Rosuvastatin (RSV) is one of the most potent statins.” NCT02284503 ↗ “subgingival delivery of 1.2% Rosuvastatin (RSV) gel” NCT02985099 ↗ “rosuvastatin 20 mg (RSV) alone.” PMID 28057081 ↗ Jan 2017
Known as	SUVAROODT	“Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg” NCT06153433 ↗
Known as	Suvast	“Suvast tablet 10 mg (Rosuvastatin 10 mg)” NCT04700436 ↗
Action	Inhibit	“rosuvastatin treatment downregulates LPS-induced inflammatory responses, serum hsCRP, and monocyte TLR4 expression” NCT00295373 ↗
Modality	Small molecule	“treatment with statins” PMID 19810001 ↗ Sep 2009
Route	Oral	“Oral” NCT00239681 ↗
Target	HMGCR	“the HMG-CoA reductase inhibitor Rosuvastatin” NCT00505154 ↗